Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

By B. Neal, V. Perkovic, K. Mahaffey, D. de Zeeuw, G. Fulcher, N. Erondu, Wayne Shaw, G. Law, Mehul Desai, D. Matthews. New England Journal of Medicine, 2017

3,907 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/217dea76f9fb1b91292ebf7cc128d9e23855e4e8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. A. Chait
2. Laura J. den Hartigh

In Surgery

1. A. Chait
2. Laura J. den Hartigh

Citations in the corpus

• GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, neutral): “Numbers in symbols identify the clinical trials: 1: REWIND (dulaglutide) [98], 4: LEADER (liraglutide) [96], 5: EXCSEL (once-weekly exeDECLARE-TIMI-58 (dapagliflozin) [121], 9: CANVAS program (canagliflozin) [122]; 10: es Association); 11: EXAMINE (alogliptin) [123], 12 CARMELINA (linagliptin) [124]”